Reducing anthracycline-induced cardiotoxicity through pharmacogenetics

[...]this variant may be linked to reduced elimination of anthracyclines or anthracycline metabolites. [...]while a more complete picture of the functional roles of RARG, SLC28A3 and UGT1A6 is still developing, there is strong evidence of their involvement in ACT. The future of pharmacogenetics for...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2018-10, Vol.19 (15), p.1147-1150
Main Authors: Scott, Erika, Hasbullah, Jafar S, Ross, Colin JD, Carleton, Bruce C
Format: Article
Language:English
Subjects:
adverse drug reactions
Animals
Anthracycline
anthracycline-induced cardiotoxicity
Anthracyclines - adverse effects
Breast cancer
Cancer
Cardiac function
Cardiomyocytes
Cardiotoxicity - etiology
Cardiotoxicity - genetics
Cardiotoxicity - prevention & control
Cardiovascular diseases
Clinical medicine
Deoxyribonucleic acid
DNA
Drug dosages
Gene expression
Genetic testing
Genomes
Heart failure
Humans
Metabolites
Patients
Pediatrics
Pharmacogenetics
Pharmacogenetics - methods
pharmacogenomics
Prevention
Risk factors
Stem cells
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]this variant may be linked to reduced elimination of anthracyclines or anthracycline metabolites. [...]while a more complete picture of the functional roles of RARG, SLC28A3 and UGT1A6 is still developing, there is strong evidence of their involvement in ACT. The future of pharmacogenetics for ACT Recently, the American Heart Association (AHA) published a scientific statement on cardiovascular disease and breast cancer, highlighting the risk factors and effects of chemotherapeutics on the heart as well as prevention strategies to reduce cardiotoxicity (20). [...]there have now been over 25 genes associated with ACT, and clinical practice guidelines have been developed and implemented for three of these. Financial and competing interests disclosure Financial support was received from the following government-funded agencies in Canada: Canada Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR), Genome Canada, Genome British Columbia and the Provincial Health Services Authority, the University of British Columbia (UBC), and British Columbia Children's Hospital Research Institute.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2018-0124